Interception inception

What Janssen hopes to achieve with first disease interception trial in Type I diabetes

The first clinical trial to come from the Janssen Research & Development LLC's Disease Interception Accelerator will move upstream from the way Type I diabetes is treated today, even if it doesn't directly prevent the disease, and help parent company Johnson & Johnson build a new hypothesis about how to prevent or delay its onset.

Janssen is already exploring disease interception within its core therapeutic areas, and previously told BioCentury that it plans to begin a trial to intercept inflammatory bowel disease (IBD) in 2017.

The diabetes trial is the first to come from the DIA, a group launched last year dedicated to exploring ways to interrupt the transition from health to disease. So far the group has announced research programs

Read the full 1220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers